LV Prasad Eye Institute Trials

LV Prasad Eye Institute	Welcome, Profile Billing Logout

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Singh, Vivek -

HERF-SSC-SCP-01, NCT04932629: To Evaluate the Clinical Safety and Efficacy of Limbal Stem Cell for Treatment of Superficial Corneal Pathologies".

Not yet recruiting

Ex-vivo cultivated Allogeneic limbal stromal stem cells

L.V. Prasad Eye Institute

Corneal Scars and Opacities

12/21

01/23

Narayanan, Raja

ERPL-CTP-001, NCT06394232: Safety & Efficacy of Eyecyte-RPE™ in Patients With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration.

Recruiting

1/2

RoW

Eyecyte-RPE™, Subretinal Injection, Oral Tacrolimus, Oral Mycophenolate Sodium

Eyestem Research Pvt. Ltd.

Retinal Disease, Macular Degeneration, Age-Related Macular Degeneration, Geographic Atrophy, Eye Diseases

04/25

12/30

Liu, Lin

ERASE, NCT06093191: Tobramycin Inhalation Solution for Pseudomonas Aeruginosa Eradication in Bronchiectasis

Recruiting

364

RoW

Tobramycin Inhalant Product, Inhaled antibiotics, Ciprofloxacin 750 MG, Oral antibiotics, Oral ciprofloxacin placebo, Natural saline inhalation, Inhaled saline

Shanghai Pulmonary Hospital, Shanghai, China

Bronchiectasis Adult, Pseudomonas Aeruginosa Infection

10/25

12/25

NCT05003245: Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD

Completed

407

RoW

HLX04-O，recombinant anti-vascular endothelial growth factor (VEGF) humanized monoclonal antibody ophthalmic injection, Lucentis

Shanghai Henlius Biotech

Age Related Macular Degeneration

05/24

NCT06708156: The Effectiveness and Safety of Two Low-concentration Atropine Sulfate Eye Drops (0.01%/0.02%) for Delaying the Pediatric Myopia Progression

Recruiting

606

RoW

Atropine sulfate eye drops 0.01%, Atropine sulfate eye drops 0.02%, Placebo eye drops

Oupushifang Pharmaceutical Technology Co., Ltd., Seefunge Pharmaceutical Technology Co., Ltd., AUTEK China Inc.

Myopia, Myopia Progression

12/26

12/27

NCT04586478: Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma

Recruiting

RoW

single dose of CNCT19

Juventas Cell Therapy Ltd.

Non-Hodgkin's Lymphoma

03/24

09/25

NCT05807347: Venetoclax Combined With Azacitidine and CAG in Refractory/Relapse Acute Myeloid Leukemia

Recruiting

RoW

Venetoclax, Azacitidine, Cytarabine, Aclacinomycin, Granulocyte colony-stimulating factor

Hematology department of the 920th hospital

Refractory/Relapse Acute Myeloid Leukemia

02/24

02/26

NCT05688696: Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Systemic Lupus Erythematosus

Recruiting

186

RoW

Orelabrutinib (Low Dose), Orelabrutinib (High Dose), Orelabrutinib Placebo

Beijing InnoCare Pharma Tech Co., Ltd.

Systemic Lupus Erythematosus, SLE

08/25

05/26

KMHD-01, NCT05662956: A Clinical Study of VA-CAG as Induction Therapy in Newly Diagnosed AML Patients

Recruiting

1/2

104

RoW

Venetoclax in combination with azacitidine and CAG, VA-CAG regimen

Hematology department of the 920th hospital

Acute Myeloid Leukemia

08/24

09/24

NCT06387082: A Clinical Study of HMPL-506 in Patients With Hematological Malignancies

Recruiting

132

RoW

HMPL-506, Two strengths of HMPL-506 tablets (25 mg and 100 mg) will be used for this clinical study

Hutchmed

Hematological Malignancies

10/27

12/27

NCT04606433: Phase I Clinical Study of GNC-038 in Patients With Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia

Recruiting

RoW

GNC-038

Sichuan Baili Pharmaceutical Co., Ltd., SystImmune Inc.

Non Hodgkin Lymphoma, Acute Lymphoblastic Leukemia

06/25

11/25

NCT06702683: The Correlation Between Blood Concentration of Sintilimab and Efficacy and Adverse Reactions in Patients with Advanced Gastric Cancer

Recruiting

N/A

112

RoW

Lin Liu

Gastric Carcinoma, Gastric Neoplasm, Gastric (cardia, Body) Cancer, Gastric Cancer Adenocarcinoma Metastatic

06/25

12/25

NCT06164821: Clinical Observation of Luspatercept in Treatment of Chinese Adult β-thalassaemia Patients With TD β-thalassemia

Recruiting

N/A

RoW

luspatercept

Hematology department of the 920th hospital

Effect of Drug

01/24

11/24

NCT05485103: A Prospective Study of the Effect of Modified Colonoscopy Bowel Preparation Program on Intestinal Cleaning, Examination and Disease in Patients With Inflammatory Bowel Disease

Recruiting

N/A

144

RoW

Polyethylene Glycols, glycerin enema, asol

Peking Union Medical College Hospital

Inflammatory Bowel Diseases

07/24

12/24

NCT06760273: Long-term Impact of Inhaled Tobramycin for Pseudomonas Aeruginosa Eradication in Bronchiectasis (ERASE II)

Recruiting

N/A

364

RoW

No Intervention: Observational Cohort

Shanghai Pulmonary Hospital, Shanghai, China

Bronchiectasis Adult

12/27

NCT06900062: The C-BRIDGE Study: China Bronchiectasis Research Involving Databases, Genomics, and Endotyping

Recruiting

N/A

1500

RoW

Shanghai Pulmonary Hospital, Shanghai, China

Bronchiectasis Adult

12/27

01/29

SHORT, NCT07010588: Comparison of ultraSound, Abbreviated MRI witH and Without HBP aS mOdalities for HCC suRveillance in patienTs With High Risk

Not yet recruiting

N/A

1389

RoW

non-contrast abbreviated MRI (NC-AMRI), enhanced abbreviated MRI (E-AMRI)

Peking University People's Hospital, National Research Institute for Family Planning

Hepatocellular Carcinoma (HCC), Magnetic Resonance Imaging (MRI), Randomized Controlled Trial

06/28

06/30

NCT05243836: S.T.O.P.® Technology Contact Lenses Versus Dual-focus Contact Lenses for Slowing Down Myopia Progression in Children

Recruiting

N/A

441

Europe, RoW

S.T.O.P® F2, S.T.O.P® DT, MiSight®

nthalmic Pty Ltd, Brighten Optix Corporation

Myopia

01/28

Sangwan, Virender S

NCT03749317: Trial to Evaluate the Efficacy and Safety of IVIEW-1201 in Acute Viral Conjunctivitis

Completed

135

RoW

IVIEW-1201, Treatment Arm, Placebo, Placebo Treatment Arm

IVIEW Therapeutics Inc.

Adenoviral Conjunctivitis

12/23

Basu, Sayan

HERF-SSC-SCP-01, NCT04932629: To Evaluate the Clinical Safety and Efficacy of Limbal Stem Cell for Treatment of Superficial Corneal Pathologies".

Not yet recruiting

Ex-vivo cultivated Allogeneic limbal stromal stem cells

L.V. Prasad Eye Institute

Corneal Scars and Opacities

12/21

01/23

Kekunnaya, Ramesh

DESDEE, NCT05242510: Evaluation of Exotropia After Patching the Eye or After Prism Adaptation

Terminated

N/A

Europe, Canada, US, RoW

Patching, Prism Adaptation

University of Rochester

Exotropia

09/24

Verkicharla, Pavan K

SLIMS, NCT04618510: SEED-LVPEI Myopia Study

Active, not recruiting

N/A

108

RoW

SEED 1-dayPure EDOF soft contact lens, Single Vision Spectacles

L.V. Prasad Eye Institute, SEED Co. Ltd.

Myopia

08/21

08/22

NCT06137560: Spectacle Films Utilising S.T.O.P.® Technology for Slowing Down Myopia Progression in Children

Recruiting

N/A

210

RoW

Single vision spectacle lens, Single vision spectacle lens + S.T.O.P.® Kit 1, Single vision spectacle lens + S.T.O.P.® Kit 2, Single vision spectacle lens + S.T.O.P.® Film, Standard single vision spectacle lens + S.T.O.P.® Kit 1 or 2

nthalmic Pty Ltd, Zhong Jing Wei Shi (Suzhou) Optical Technology Ltd.

Myopia

09/26

NCT05243836: S.T.O.P.® Technology Contact Lenses Versus Dual-focus Contact Lenses for Slowing Down Myopia Progression in Children

Recruiting

N/A

441

Europe, RoW

S.T.O.P® F2, S.T.O.P® DT, MiSight®

nthalmic Pty Ltd, Brighten Optix Corporation

Myopia

01/28

Zhou, Xing Tao

NCT06137560: Spectacle Films Utilising S.T.O.P.® Technology for Slowing Down Myopia Progression in Children

Recruiting

N/A

210

RoW

nthalmic Pty Ltd, Zhong Jing Wei Shi (Suzhou) Optical Technology Ltd.

Myopia

09/26

NCT05243836: S.T.O.P.® Technology Contact Lenses Versus Dual-focus Contact Lenses for Slowing Down Myopia Progression in Children

Recruiting

N/A

441

Europe, RoW

S.T.O.P® F2, S.T.O.P® DT, MiSight®

nthalmic Pty Ltd, Brighten Optix Corporation

Myopia

01/28

Gupta, Satish K

NCT05243836: S.T.O.P.® Technology Contact Lenses Versus Dual-focus Contact Lenses for Slowing Down Myopia Progression in Children

Recruiting

N/A

441

Europe, RoW

S.T.O.P® F2, S.T.O.P® DT, MiSight®

nthalmic Pty Ltd, Brighten Optix Corporation

Myopia

01/28

Maldoddi, Rakesh

NCT05243836: S.T.O.P.® Technology Contact Lenses Versus Dual-focus Contact Lenses for Slowing Down Myopia Progression in Children

Recruiting

N/A

441

Europe, RoW

S.T.O.P® F2, S.T.O.P® DT, MiSight®

nthalmic Pty Ltd, Brighten Optix Corporation

Myopia

01/28

Panigrahi, Swati

NCT05243836: S.T.O.P.® Technology Contact Lenses Versus Dual-focus Contact Lenses for Slowing Down Myopia Progression in Children

Recruiting

N/A

441

Europe, RoW

S.T.O.P® F2, S.T.O.P® DT, MiSight®

nthalmic Pty Ltd, Brighten Optix Corporation

Myopia

01/28

Anthony, Megha

NCT05243836: S.T.O.P.® Technology Contact Lenses Versus Dual-focus Contact Lenses for Slowing Down Myopia Progression in Children

Recruiting

N/A

441

Europe, RoW

S.T.O.P® F2, S.T.O.P® DT, MiSight®

nthalmic Pty Ltd, Brighten Optix Corporation

Myopia

01/28

Corominas, Nuria Tomas

NCT05243836: S.T.O.P.® Technology Contact Lenses Versus Dual-focus Contact Lenses for Slowing Down Myopia Progression in Children

Recruiting

N/A

441

Europe, RoW

S.T.O.P® F2, S.T.O.P® DT, MiSight®

nthalmic Pty Ltd, Brighten Optix Corporation

Myopia

01/28

Strube, Yi Ning

DESDEE, NCT05242510: Evaluation of Exotropia After Patching the Eye or After Prism Adaptation

Terminated

N/A

Europe, Canada, US, RoW

Patching, Prism Adaptation

University of Rochester

Exotropia

09/24

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Singh, Vivek -

HERF-SSC-SCP-01, NCT04932629: To Evaluate the Clinical Safety and Efficacy of Limbal Stem Cell for Treatment of Superficial Corneal Pathologies".

Not yet recruiting

Ex-vivo cultivated Allogeneic limbal stromal stem cells

L.V. Prasad Eye Institute

Corneal Scars and Opacities

12/21

01/23

Narayanan, Raja

ERPL-CTP-001, NCT06394232: Safety & Efficacy of Eyecyte-RPE™ in Patients With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration.

Recruiting

1/2

RoW

Eyecyte-RPE™, Subretinal Injection, Oral Tacrolimus, Oral Mycophenolate Sodium

Eyestem Research Pvt. Ltd.

Retinal Disease, Macular Degeneration, Age-Related Macular Degeneration, Geographic Atrophy, Eye Diseases

04/25

12/30

Liu, Lin

ERASE, NCT06093191: Tobramycin Inhalation Solution for Pseudomonas Aeruginosa Eradication in Bronchiectasis

Recruiting

364

RoW

Tobramycin Inhalant Product, Inhaled antibiotics, Ciprofloxacin 750 MG, Oral antibiotics, Oral ciprofloxacin placebo, Natural saline inhalation, Inhaled saline

Shanghai Pulmonary Hospital, Shanghai, China

Bronchiectasis Adult, Pseudomonas Aeruginosa Infection

10/25

12/25

NCT05003245: Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD

Completed

407

RoW

HLX04-O，recombinant anti-vascular endothelial growth factor (VEGF) humanized monoclonal antibody ophthalmic injection, Lucentis

Shanghai Henlius Biotech

Age Related Macular Degeneration

05/24

NCT06708156: The Effectiveness and Safety of Two Low-concentration Atropine Sulfate Eye Drops (0.01%/0.02%) for Delaying the Pediatric Myopia Progression

Recruiting

606

RoW

Atropine sulfate eye drops 0.01%, Atropine sulfate eye drops 0.02%, Placebo eye drops

Oupushifang Pharmaceutical Technology Co., Ltd., Seefunge Pharmaceutical Technology Co., Ltd., AUTEK China Inc.

Myopia, Myopia Progression

12/26

12/27

NCT04586478: Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma

Recruiting

RoW

single dose of CNCT19

Juventas Cell Therapy Ltd.

Non-Hodgkin's Lymphoma

03/24

09/25

NCT05807347: Venetoclax Combined With Azacitidine and CAG in Refractory/Relapse Acute Myeloid Leukemia

Recruiting

RoW

Venetoclax, Azacitidine, Cytarabine, Aclacinomycin, Granulocyte colony-stimulating factor

Hematology department of the 920th hospital

Refractory/Relapse Acute Myeloid Leukemia

02/24

02/26

NCT05688696: Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Systemic Lupus Erythematosus

Recruiting

186

RoW

Orelabrutinib (Low Dose), Orelabrutinib (High Dose), Orelabrutinib Placebo

Beijing InnoCare Pharma Tech Co., Ltd.

Systemic Lupus Erythematosus, SLE

08/25

05/26

KMHD-01, NCT05662956: A Clinical Study of VA-CAG as Induction Therapy in Newly Diagnosed AML Patients

Recruiting

1/2

104

RoW

Venetoclax in combination with azacitidine and CAG, VA-CAG regimen

Hematology department of the 920th hospital

Acute Myeloid Leukemia

08/24

09/24

NCT06387082: A Clinical Study of HMPL-506 in Patients With Hematological Malignancies

Recruiting

132

RoW

HMPL-506, Two strengths of HMPL-506 tablets (25 mg and 100 mg) will be used for this clinical study

Hutchmed

Hematological Malignancies

10/27

12/27

NCT04606433: Phase I Clinical Study of GNC-038 in Patients With Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia

Recruiting

RoW

GNC-038

Sichuan Baili Pharmaceutical Co., Ltd., SystImmune Inc.

Non Hodgkin Lymphoma, Acute Lymphoblastic Leukemia

06/25

11/25

NCT06702683: The Correlation Between Blood Concentration of Sintilimab and Efficacy and Adverse Reactions in Patients with Advanced Gastric Cancer

Recruiting

N/A

112

RoW

Lin Liu

Gastric Carcinoma, Gastric Neoplasm, Gastric (cardia, Body) Cancer, Gastric Cancer Adenocarcinoma Metastatic

06/25

12/25

NCT06164821: Clinical Observation of Luspatercept in Treatment of Chinese Adult β-thalassaemia Patients With TD β-thalassemia

Recruiting

N/A

RoW

luspatercept

Hematology department of the 920th hospital

Effect of Drug

01/24

11/24

NCT05485103: A Prospective Study of the Effect of Modified Colonoscopy Bowel Preparation Program on Intestinal Cleaning, Examination and Disease in Patients With Inflammatory Bowel Disease

Recruiting

N/A

144

RoW

Polyethylene Glycols, glycerin enema, asol

Peking Union Medical College Hospital

Inflammatory Bowel Diseases

07/24

12/24

NCT06760273: Long-term Impact of Inhaled Tobramycin for Pseudomonas Aeruginosa Eradication in Bronchiectasis (ERASE II)

Recruiting

N/A

364

RoW

No Intervention: Observational Cohort

Shanghai Pulmonary Hospital, Shanghai, China

Bronchiectasis Adult

12/27

NCT06900062: The C-BRIDGE Study: China Bronchiectasis Research Involving Databases, Genomics, and Endotyping

Recruiting

N/A

1500

RoW

Shanghai Pulmonary Hospital, Shanghai, China

Bronchiectasis Adult

12/27

01/29

SHORT, NCT07010588: Comparison of ultraSound, Abbreviated MRI witH and Without HBP aS mOdalities for HCC suRveillance in patienTs With High Risk

Not yet recruiting

N/A

1389

RoW

non-contrast abbreviated MRI (NC-AMRI), enhanced abbreviated MRI (E-AMRI)

Peking University People's Hospital, National Research Institute for Family Planning

Hepatocellular Carcinoma (HCC), Magnetic Resonance Imaging (MRI), Randomized Controlled Trial

06/28

06/30

NCT05243836: S.T.O.P.® Technology Contact Lenses Versus Dual-focus Contact Lenses for Slowing Down Myopia Progression in Children

Recruiting

N/A

441

Europe, RoW

S.T.O.P® F2, S.T.O.P® DT, MiSight®

nthalmic Pty Ltd, Brighten Optix Corporation

Myopia

01/28

Sangwan, Virender S

NCT03749317: Trial to Evaluate the Efficacy and Safety of IVIEW-1201 in Acute Viral Conjunctivitis

Completed

135

RoW

IVIEW-1201, Treatment Arm, Placebo, Placebo Treatment Arm

IVIEW Therapeutics Inc.

Adenoviral Conjunctivitis

12/23

Basu, Sayan

HERF-SSC-SCP-01, NCT04932629: To Evaluate the Clinical Safety and Efficacy of Limbal Stem Cell for Treatment of Superficial Corneal Pathologies".

Not yet recruiting

Ex-vivo cultivated Allogeneic limbal stromal stem cells

L.V. Prasad Eye Institute

Corneal Scars and Opacities

12/21

01/23

Kekunnaya, Ramesh

DESDEE, NCT05242510: Evaluation of Exotropia After Patching the Eye or After Prism Adaptation

Terminated

N/A

Europe, Canada, US, RoW

Patching, Prism Adaptation

University of Rochester

Exotropia

09/24

Verkicharla, Pavan K

SLIMS, NCT04618510: SEED-LVPEI Myopia Study

Active, not recruiting

N/A

108

RoW

SEED 1-dayPure EDOF soft contact lens, Single Vision Spectacles

L.V. Prasad Eye Institute, SEED Co. Ltd.

Myopia

08/21

08/22

NCT06137560: Spectacle Films Utilising S.T.O.P.® Technology for Slowing Down Myopia Progression in Children

Recruiting

N/A

210

RoW

nthalmic Pty Ltd, Zhong Jing Wei Shi (Suzhou) Optical Technology Ltd.

Myopia

09/26

NCT05243836: S.T.O.P.® Technology Contact Lenses Versus Dual-focus Contact Lenses for Slowing Down Myopia Progression in Children

Recruiting

N/A

441

Europe, RoW

S.T.O.P® F2, S.T.O.P® DT, MiSight®

nthalmic Pty Ltd, Brighten Optix Corporation

Myopia

01/28

Zhou, Xing Tao

NCT06137560: Spectacle Films Utilising S.T.O.P.® Technology for Slowing Down Myopia Progression in Children

Recruiting

N/A

210

RoW

nthalmic Pty Ltd, Zhong Jing Wei Shi (Suzhou) Optical Technology Ltd.

Myopia

09/26

NCT05243836: S.T.O.P.® Technology Contact Lenses Versus Dual-focus Contact Lenses for Slowing Down Myopia Progression in Children

Recruiting

N/A

441

Europe, RoW

S.T.O.P® F2, S.T.O.P® DT, MiSight®

nthalmic Pty Ltd, Brighten Optix Corporation

Myopia

01/28

Gupta, Satish K

NCT05243836: S.T.O.P.® Technology Contact Lenses Versus Dual-focus Contact Lenses for Slowing Down Myopia Progression in Children

Recruiting

N/A

441

Europe, RoW

S.T.O.P® F2, S.T.O.P® DT, MiSight®

nthalmic Pty Ltd, Brighten Optix Corporation

Myopia

01/28

Maldoddi, Rakesh

NCT05243836: S.T.O.P.® Technology Contact Lenses Versus Dual-focus Contact Lenses for Slowing Down Myopia Progression in Children

Recruiting

N/A

441

Europe, RoW

S.T.O.P® F2, S.T.O.P® DT, MiSight®

nthalmic Pty Ltd, Brighten Optix Corporation

Myopia

01/28

Panigrahi, Swati

NCT05243836: S.T.O.P.® Technology Contact Lenses Versus Dual-focus Contact Lenses for Slowing Down Myopia Progression in Children

Recruiting

N/A

441

Europe, RoW

S.T.O.P® F2, S.T.O.P® DT, MiSight®

nthalmic Pty Ltd, Brighten Optix Corporation

Myopia

01/28

Anthony, Megha

NCT05243836: S.T.O.P.® Technology Contact Lenses Versus Dual-focus Contact Lenses for Slowing Down Myopia Progression in Children

Recruiting

N/A

441

Europe, RoW

S.T.O.P® F2, S.T.O.P® DT, MiSight®

nthalmic Pty Ltd, Brighten Optix Corporation

Myopia

01/28

Corominas, Nuria Tomas

NCT05243836: S.T.O.P.® Technology Contact Lenses Versus Dual-focus Contact Lenses for Slowing Down Myopia Progression in Children

Recruiting

N/A

441

Europe, RoW

S.T.O.P® F2, S.T.O.P® DT, MiSight®

nthalmic Pty Ltd, Brighten Optix Corporation

Myopia

01/28

Strube, Yi Ning

DESDEE, NCT05242510: Evaluation of Exotropia After Patching the Eye or After Prism Adaptation

Terminated

N/A

Europe, Canada, US, RoW

Patching, Prism Adaptation

University of Rochester

Exotropia

09/24



	Diseases Companies Products Productz Mechanisms of Action Sites